Anika Therapeutics (ANIK) EBT (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of EBT data on file, last reported at -$4.8 million in Q1 2026.

• EBT for Q1 2026 came in at -$4.8 million, down 24.61% year-over-year; the trailing twelve-month figure through Mar 2026 was -$12000.0 (up 99.8% YoY), and the FY2025 annual result was $940000.0, up 123.05% from the prior year.
• EBT declined to -$4.8 million in Q1 2026 per ANIK's latest filing, from $11.0 million in the prior quarter.
• Over five years, EBT peaked at $25.3 million in Q4 2023 and troughed at -$12.0 million in Q1 2023.
• A 5-year average of -$262882.4 and a median of -$3.1 million in 2023 frame the typical range for EBT.
• On a YoY basis, EBT climbed as much as 963.61% in 2025 and fell as far as 788.0% in 2025.
• A 5-year view of EBT shows it stood at $12.7 million in 2022, then jumped by 99.22% to $25.3 million in 2023, then slumped by 105.04% to -$1.3 million in 2024, then jumped by 963.61% to $11.0 million in 2025, then plunged by 143.78% to -$4.8 million in 2026.
• Business Quant data shows ANIK's EBT at -$4.8 million in Q1 2026, $11.0 million in Q4 2025, and -$2.2 million in Q3 2025.